Category Archives: Artificial Intelligence

ST. PETERSBURG, Fla. There have been plenty of news reports about labor shortages and businesses unable to fill positions throughout the pandemic. But, there is another side of this story that hasn't gotten enough attention; millions of people looking for jobs and can't get hired because of online algorithms, artificial intelligence, and more.

ABC Action News reporter Michael Paluska sat down with St. Petersburg resident Elizabeth Longden. She showed us all of the jobs she's applied for on LinkedIn and Indeed. More than a thousand applications were filed on LinkedIn and more than 140 on Indeed.

"So, business data strategy, talent and culture recruiter, diversity, equity and inclusion specialist, human resources," Longden said as she named off a few of the jobs she's applied for. "There are 128 pages with eight applications per page."

"That's a lot of jobs," Paluska said.

"Yeah, a lot," Longden replied with a half-smile that was more of an acknowledgment of her job woes.

"How do you process 1,000 plus rejections?" Paluska asked.

"It's discouraging, and fortunately, there haven't been 1,000 rejections. Most of the places don't even get back to you one way or the other," Longden said. "So yeah, we're looking at less than that. But it's still a big, you know, it's a big confidence blow, especially when you hear, oh, there's a labor crisis. And nobody wants to work. And like, hi, I would like to work."

According to the Bureau of Labor, a record 4.4 million people quit their jobs in September. That's a new all-time high. So, you would think millions of openings would help Longden. But, that's not the case.

Longden has a college degree, an insurance license, and a decade of work experience in human resources. In May, like many Americans throughout this pandemic, she was laid off from her company. So she took about a month off to reset and started the search in her field as an operations specialist, people ops, HR, and businesses operations.

"Have you ever been in a hole where you lost a job, and you couldn't get another one in the past?" Paluska asked.

"Not where I had lost one and couldn't get another one. I'd had times where I'd moved, you know, and had had trouble finding a job for maybe a month or two. But I was always able to find something," Longden said.

In September, the Harvard Business School released a study called Untapped Workers: Hidden Talent. The study explains this lack of hiring phenomenon. The lead author, Joseph Fuller, estimating millions of Americans are in the same position as Longden.

"So, you have this, this system that systematically excludes people that may not check every box in the employer's description of what they're looking for, but can be highly qualified on multiple parameters, even those the most important for job success, but they still get excluded," Fuller, professor of management practice at Harvard Business School said. "But what happens is, the employer in setting up these filters and ranking systems emphasizes some skills over others, intended to rely on two factors to make a decision."

The job search algorithms and artificial intelligence filter out candidates based on keywords before someone like Longden ever talks to a human being.

"And, the algorithms are unforgiving," Fuller said. "If you don't, if you don't have the right keywords, if you're just missing one of those attributes, you can get excluded from consideration even though you check every box on every other attribute they're looking for."

"Whose fault is that the company or LinkedIn or Indeed?" Paluska asked.

"You know, no company sets out to have a failed hiring process," Fuller said. "They provide the tools that their customers regularly ask for. So I think this is a tragedy, without a villain. It's the way companies have gone about it is optimized around minimizing the time it takes to find candidates in minimizing the cost of finding someone to hire. There's some kind of killer variable that is causing the system to say not qualified or not attractive relative to other applicants. The vast majority of those candidates never hear back anything just ghosted."

Longden has been ghosted a lot. One recruiter called her three times in a week asking for her to apply and when she thought she got the job, radio silence. Longden thought he was dead.

"I even was like, 'Are you alive?' You know, like, I just want to know, you're okay, you've just totally gone dark," Longden said.

Longden's job search hell has her skeptical of the entire process.

"I've also discovered that there's been a huge uptick in companies wanting pre-work from people. So all in all, I've probably done about 25 hours worth of pre-work for various companies, none of which has been compensated, and none of which I've even gotten a roll-out of," Longden said.

"Do you think they are using your work for their benefit?" Paluska asked.

"Oh, I'm sure," Longden said. "One of the things I was asked to create was an onboarding process for new employees. So that's what the role at the company would have been doing was onboarding their new employees as they came in. And so, one of the pre-work examples was to create an onboarding process from the offer to the 90-day mark of employment. And I did that. And I'm certain that they're having multiple people do that and pulling what they like best from everyone."

We reached out to LinkedIn and Indeed for comments but did not get a response back.

"Two or three quick suggestions for Elizabeth, the first is be very, very aware of language terms, and make your submission. Match what's being asked for, to the greatest degree you can with integrity," Fuller said. "The second thing I would say is, go on something like LinkedIn and look at the profiles of people who got the job you want. And what are they saying they do? What keywords are they using? Is there a regularly referenced tool that they claim expertise in that she doesn't have?"

Excerpt from:

Job hunting nightmare: 1,000 plus job applications and still no offers - ABC Action News

DUBLIN, Nov. 25, 2021 /PRNewswire/ -- The "Endoscopy Devices Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The endoscopy devices global market is expected to reach $39,475.6 million by 2028 growing at a high single digit CAGR from 2021 to 2028

Due to persistently escalating prevalence, and incidence of chronic diseases across the globe, and the need for early diagnostic, and therapeutic interventions, increasing inclination of patients towards the minimally invasive therapeutic procedures, gradual transition of endoscopy devices market towards single-use endoscopes, the emergence of technologically advanced endoscopy products, the trend of acquisitions, and collaborations in the endoscopy device industry, and the increasing awareness, and adoption of the highly beneficial endoscopic procedures across the emerging nations.

Endoscopy is a minimally invasive or non-invasive medical procedure that utilizes specialized devices like endoscopes for the detailed inspection or assessment, and manipulation or treatment of diseased organs or tissues by visualizing the internal organ or area of interest.

The constantly advancing various emergency or elective endoscopy procedures are being used for the timely diagnosis, and minimally-traumatic treatment of various chronic ailments like cancer, arthritis, joint injuries, inflammatory bowel diseases (IBD), chronic pancreatitis, obesity, Barrett's esophagus, and others.

Robot-Assisted Endoscopes, and artificial intelligence (AI) powered endoscopes segment is expected to be the fastest emerging segment growing with a double digit CAGR from 2021 to 2028 due to the emergence of several Robot Assisted Endoscopes, and AI guided endoscopy systems in the market, and the promising potential of robot-assisted endoscopes, and AI-enhanced endoscopy systems to mitigate the labor intensity of endoscopic procedures, and increase the precision, and safety of endoscopic procedures.

Story continues

Key Topics Covered:

1 Executive Summary

2 Introduction

3 Market Analysis3.1 Introduction3.2 Market Segmentation3.3 Factors Influencing Market3.3.1 Drivers, and Opportunities3.3.1.1 Persistently Escalating Incidence, and Prevalence of Chronic Diseases, and the Need for Early Diagnosis, and Treatment3.3.1.2 Increasing Inclination Towards Minimally Invasive Therapeutic Procedures3.3.1.3 the Gradual Endoscopy Market Conversion from Reusable to Single-Use Endoscopes3.3.1.4 the Emergence of Technologically Advanced Endoscopy Products3.3.1.5 Persistently Elevating Geriatric Population with Chronic Diseases3.3.1.6 Acquisitions and Collaborations to Open An Array of Opportunities for the Market to Flourish3.3.1.7 Market Expansion Opportunities in Emerging Nations3.3.2 Restraints, and Threats3.3.2.1 High Cost of the Endoscopy Devices, and Procedures3.3.2.2 Lack of Skilled, and Trained Professionals3.3.2.3 Increasing Concerns About the Adverse Effects Associated with Endoscopic Procedures3.3.2.4 Stringent Regulatory Bodies Guiding the Endoscopy Device Manufacturers3.3.2.5 the Threat of Non-Invasive Diagnostic, and Therapeutic Technologies3.3.2.6 Unfavorable Reimbursement Scenario for the Endoscopy Procedures3.4 Regulatory Affairs3.4.1 International Organization for Standardization3.4.1.1 Iso 9001: 2015 Quality Management System3.4.1.2 Iso 13485 Medical Devices3.4.1.3 Iso 10993 Biological Evaluation of Medical Devices3.4.2 the U.S.3.4.3 Canada3.4.4 Europe3.4.5 Japan3.4.6 China3.4.7 India3.5 Reimbursement Scenario3.5.1 Reimbursement Table3.6 Technological Advancements3.6.1 Therapeutic Capsule Endoscopes with Active Locomotion3.6.2 Molecular Endoscopic Imaging (Mei)3.6.3 Variable Stiffness Endoscopes, and Shape Locking Devices or Overtubes3.6.4 Miniaturized Endoscopes3.6.5 3D Endoscopes3.6.6 Notes, and Less3.6.7 Advanced Diagnostic Imaging Techniques3.7 Clinical Trials3.8 Endoscopes - Fda, and Ce Regulatory Approval Analysis3.9 Patent Analysis3.10 Single-Use Endoscopes Market3.11 Automated Endoscope Reprocessors (Aer) Market3.12 Refurbished Endoscopy Devices Market3.13 Porter's Five Force Analysis3.14 Supply Chain Analysis3.15 Average Selling Price (ASP) of Select Endoscopy Devices3.16 Impact of COVID-19 on Endoscopy Devices Industry3.17 Market Share Analysis3.18 Endoscopy Devices Company Comparison Table by Revenue, Product, Product Type, and Application

4 Endoscopy Devices Global Market, by Applications4.1 Introduction4.2 Arthroscopy4.3 Pulmonary Endoscopy4.4 Ent Endoscopy4.5 Gastrointestinal Endoscopy4.6 Gynecology/Obstetrics4.7 Neuroendoscopy4.8 Urological Endoscopy4.9 Laparoscopy

5 Endoscopy Devices Global Market, by Products5.1 Introduction5.2 Endoscopes5.3 Endoscopic Instruments5.4 Endoscopic Accessories

6 Endoscopy Devices Global Market, by End-Users6.1 Introduction6.2 Hospitals6.3 Endoscopy Ambulatory Surgery Centers or Ambulatory Endoscopy Centers6.4 Endoscopy Diagnostic Centers6.5 Other End-Users (Office Based Endoscopy (Obe) Suites, and Academic, and Research Institutes)

7 Global Endoscopy Procedural Volume7.1 Endoscopy - Number of Procedures by Region

8 Regional Market Analysis8.1 Introduction

9 Competitive Landscape9.1 Introduction9.2 Product Approval9.3 Product Launch9.4 Acquisitions9.5 Collaborations9.6 Other Developments

10 Major Player Profiles10.1 Overview10.2 Financials10.3 Product Portfolio10.4 Key Developments10.5 Business Strategy10.6 SWOT Analysis

Arthrex, Inc.

B. Braun Melsungen Ag

Boston Scientific Corporation

Fujifilm Holdings Corporation

Hoya Corporation (Pentax Medical)

Johnson & Johnson

Karl Storz Se & Co. Kg

Medtronic, plc.

Olympus Corporation

Stryker Corporation

For more information about this report visit https://www.researchandmarkets.com/r/lrp81d

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Cision

View original content:https://www.prnewswire.com/news-releases/endoscopy-devices-markets---global-forecast-to-2028-robot-assisted-endoscopes-and-artificial-intelligence-ai-powered-endoscopes-segment-is-expected-to-be-the-fastest-emerging-segment-301432111.html

SOURCE Research and Markets

Here is the original post:

Endoscopy Devices Markets - Global Forecast to 2028: Robot-Assisted Endoscopes, and Artificial Intelligence (AI) Powered Endoscopes Segment is...

GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has signed a collaboration agreement (the " Collaboration ") with InveniAI LLC (" InveniAI "), a U.S. based company that has pioneered the application of artificial intelligence and machine learning across biopharma and other industries, in order to identify promising drug candidates to treat rare and specialty diseases.

Under the terms of the Collaboration, InveniAI will use its proprietary platform for the identification of potential pharmaceutical product opportunities using its Pharma Big Data Innovation Lab (" Platform "), consisting of (i) its proprietary AlphaMeld(R) platform, a cloud-based Artificial Intelligence (" AI ") platform that utilizes proprietary machine learning and deep learning based neural networks to identify product opportunities in therapeutic areas, (ii) its cross-functional teams at its Integrated Center of Excellence, and (iii) domain expertise, to generate novel pharmaceutical opportunities and the related development pathway for the development of such concepts.

In the Collaboration, it is expected that InveniAI will utilize its Platform to navigate the volume of data for all regulatory agency approved drugs and their associated active ingredients (Active Pharmaceutical Ingredient (" API ")) to identify potential rare and specialty disease indications for development and commercialization by Relief (" Product Concepts "). InveniAI will seek to prioritize top Product Concepts, associated diseases, scientific packages and evidence to support the potential drug development opportunities by Relief. Relief anticipates InveniAI's Platform will complement its wholly owned subsidiary APR Applied Pharma Research SA's existing capabilities in research and development and drug reformulation. Based on product leads developed by InveniAI, Relief hopes to develop proprietary versions of existing drugs, and to protect those drugs with long-lived intellectual property and defensible patent claims.

Story continues

Under the terms of the Collaboration, Relief will pay InveniAI an initial up-front fee, success milestones and commercialization royalties for the full development program. Additional financial details were not disclosed.

"We believe that the addition of InveniAI's AI-powered capabilities will meaningfully complement our existing drug development efforts. AI is becoming an increasingly important tool in identifying and screening new drug projects and Relief intends to fully leverage this promising technology," stated Raghuram (Ram) Selvaraju, Chairman of Relief. "In partnering with InveniAI, we are accessing decades' worth of expertise which has already led to successful drug re-innovation (e.g., vilazodone for treatment of depression and dexmedetomidine for treatment of agitation) and a proven platform that has been the basis of multiple partnerships with established companies. We believe that our work with InveniAI could generate multiple promising additions to our pipeline that may represent capital-efficient, cost-effective and risk-mitigated approaches to product development. In focusing on the optimization of existing approved APIs, we hope to ensure well-established clinical safety and tolerability for the product concepts identified at inception, giving us a running start in pursuing development of novel uses for these drugs. In our view, this approach will enable us to rapidly and efficiently execute innovation that brings relief to patients suffering from severe and debilitating conditions."

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's drug candidate, RLF-100(TM) (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH bring to Relief a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit http://www.relieftherapeutics.com . Follow us on LinkedIn.

CONTACT:RELIEF THERAPEUTICS Holding SAJack WeinsteinChief Financial Officer and Treasurercontact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:Rx Communications GroupMichael Miller+1-917-633-6086mmiller@rxir.com

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether InveniAI will bring to RELIEF THERAPEUTICS Holding SA drug candidates that can be successfully developed by RELIEF THERAPEUTICS Holding SA, (ii) whether RELIEF THERAPEUTICS Holding SA will successfully develop and ultimately market any drug candidate identified by InveniAI, and (iii) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

View source version on accesswire.com: https://www.accesswire.com/674546/Relief-Therapeutics-and-InveniAI-Sign-a-Strategic-Collaboration-Agreement-to-Identify-New-Product-Development-Opportunities-using-Artificial-Intelligence

Link:

Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial...

During extremely dry, hot, and windy weather, being able to differentiate wildfire smoke from fog and other false indicators is invaluable to analysts in PG&E Wildfire Safety Operations Center and fire agencies. Thats why PG&E is testing artificial intelligence (AI) and machine-learning capabilities in the growing network of high-definition cameras across Northern and Central California to see how it can enhance fire-watch and response capabilities.

This year, PG&E, in collaboration with ALERTWildfire, has installed 138 new HD cameras across High Fire-Threat Districts, in accordance with its 2021 Wildfire Mitigation Plan. Of those 138 cameras, 46 of them are included in the new AI testing program in partnership withAlcheraand ALERTWildfire. A similar pilot was conducted withPanothrough participation in EPRIs2021 Incubatenergy Labs Challenge.PG&E began installing HD cameras in 2018, as part of its Community Wildfire Safety Program. As of October 31, 487 cameras are now in operation.

Even with the two significant rainstorms in October and November, we are still in a historic drought and California, along with other western states, continue to experience an increase in wildfire risk and a longer wildfire season. We are using every new tool and technology at our disposal to improve situational awareness and intelligence to help mitigate and prevent wildfires, including this new AI capability, said PG&Es Sumeet Singh, chief risk officer. Every bit of data and intelligence that comes to us could potentially save a life.

Read more at PG&E

Read more here:

PG&E Testing Artificial Intelligence That Could Expand Wildfire Detection Capabilities to Growing Network of High-Definition Cameras - HS Today -...

Scientists have discovered a new lie detector that can read facial muscles that people won't even know they are using.

The study, conducted by the researchers at Tel Aviv University, has been in 'Brain and Behaviour.'

It was conducted on the basis of micro-expressions that vanish in 40 to 60 milliseconds due to which accuracy and speed played a key role.

Also read |Experts look to recycle dangerous space junk into rocket fuel in Earth's orbit

According to behavioral neuroscientist Dino Levy, ''it's not perfect, but much better than any existing [facial recognition] technology.''

''Since this was an initial study, the lie itself was very simple,'' he added.

Researchers tested the give-away indicators on 48 participants during which people had tells such twitching of eyebrows or cheek muscles.

''We successfully detected lies in all the participants and did so significantly better than untrained human detectors,'' explains Levy.

Also read |Facebook advertisers promoted false claims about climate change during COP26 summit

''Interestingly, individuals who were able to successfully deceive their human counterparts were also poorly detected by the machine-learning algorithm,'' he added.

The lie detector was driven by artificial intelligence and hopes to bring more transparency. It can also be used to ramp up border security.

Researchers believe it could make its way into the private sector, for example, to screen insurance claims or job applicants.

They usually face criticism from human rights groups that question the technologys ability to accurately assess peoples intentions and its potential for discrimination.

(With inputs from agencies)

Read more here:

Scientists discover lie detector that uses artificial intelligence to detect micro-expressions - WION

Piscataway, N.J. - 18 November 2021 -IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, today released the results of "The Impact of Technology in 2022 and Beyond: an IEEE Global Study," a new survey of global technology leaders from the U.S., U.K., China, India, and Brazil. The study, which included 350 chief technology officers, chief information officers, and IT directors, covers the most important technologies in 2022, industries most impacted by technology in the year ahead, and technology trends through the next decade.Learn moreabout the study and the impact of technology in 2022 and beyond.

The most important technologies, innovation, sustainability, and the future

Which technologies will be the most important in 2022? Among total respondents, more than one in five (21%) say AI and machine learning, cloud computing (20%), and 5G (17%) will be the most important technologies next year. Because of the global pandemic, technology leaders surveyed said in 2021 they accelerated adoption of cloud computing (60%), AI and machine learning (51%), and 5G (46%), among others.

Its not surprising, therefore, that 95% agreeincluding 66% who strongly agreethat AI will drive the majority of innovation across nearly every industry sector in the next one to five years.

When asked which of the following areas 5G will most benefit in the next year, technology leaders surveyed said:

As for industry sectors most impacted by technology in 2022, technology leaders surveyed cited manufacturing (25%), financial services (19%), healthcare (16%), and energy (13%). As compared to the beginning of 2021, 92% of respondents agree, including 60% who strongly agree, that implementing smart building technologies that benefit sustainability, decarbonization, and energy savings has become a top priority for their organization.

Workplace technologies, human resources collaboration, and COVID-19

As the impact of COVID-19 varies globally and hybrid work continues, technology leaders nearly universally agree (97% agree, including 69% who strongly agree) that their team is working more closely than ever before with human resources leaders to implement workplace technologies and apps for office check-in, space usage data and analytics, COVID and health protocols, employee productivity, engagement, and mental health.

Among challenges technology leaders see in 2022, maintaining strong cybersecurity for a hybrid workforce of remote and in-office workers is viewed by those surveyed as challenging by 83% of respondents (40% very, 43% somewhat) while managing return-to-office health and safety protocols, software, apps, and data is seen as challenging by 73% of those surveyed (29% very, 44% somewhat). Determining what technologies are needed for their company in the post-pandemic future is anticipated to be challenging for 68% of technology leaders (29% very, 39% somewhat). Recruiting technologists and filling open tech positions in the year ahead is also seen as challenging by 73% of respondents.

Robots rise over the next decade

Looking ahead, 81% agree that in the next five years, one quarter of what they do will be enhanced by robots, and 77% agree that in the same time frame, robots will be deployed across their organization to enhance nearly every business function from sales and human resources to marketing and IT. A majority of respondents agree (78%) that in the next ten years, half or more of what they do will be enhanced by robots. As for the deployments of robots that will most benefit humanity, according to the survey, those are manufacturing and assembly (33%), hospital and patient care (26%), and earth and space exploration (13%).

Connected devices continue to proliferate

As a result of the shift to hybrid work and the pandemic, more than half (51%) of technology leaders surveyed believe the number of devices connected to their businesses that they need to track and managesuch as smartphones, tablets, sensors, robots, vehicles, drones, etc.increased as much as 1.5 times, while for 42% of those surveyed the number of devices increased in excess of 1.5 times.

However, the perspectives of technology leaders globally diverge when asked about managing even more connected devices in 2022. When asked if the number of devices connected to their companys business will grow so significantly and rapidly in 2022 that it will be unmanageable, over half of technology leaders disagree (51%), but 49% agree. Those differences can also be seen across regions78% in India, 64% in Brazil, and 63% in the U.S. agree device growth will be unmanageable, while a strong majority in China (87%) and just over half (52%) in the U.K disagree.

Cyber and physical security, preparedness, and deployment of technologies

The cybersecurity concerns most likely to be in technology leaders top two are issues related to the mobile and hybrid workforce including employees using their own devices (39%) and cloud vulnerability (35%). Additional concerns include data center vulnerability (27%), a coordinated attack on their network (26%), and a ransomware attack (25%). Notably, 59% of all technology leaders surveyed currently use or in the next five years plan to use drones for security, surveillance, or threat prevention as part of their business model. There are regional disparities though. Current drone use for security or plans to do so in the next five years are strongest in Brazil (78%), China (71%), India (60%), and the U.S. (52%) compared to only (32%) in the U.K., where 48% of respondents say they have no plans to use drones in their business.

An open-source distributed database that uses cryptography through a distributed ledger, blockchain enables trust among individuals and third parties. The four uses in the next year respondents were most likely to cite in their own top three most important uses for blockchain technology are:

The vast majority of those surveyed (92%) believe that compared to a year ago, their company is better prepared to respond to a potentially catastrophic interruption such as a data breach or natural disaster. Of that majority, 65% strongly agree that COVID-19 accelerated their preparedness.

About the Survey

"The Impact of Technology in 2022 and Beyond: an IEEE Global Study" surveyed 350 CIOs, CTOs, IT directors, and other technology leaders in the U.S., China, U.K., India, and Brazil at organizations with more than 1,000 employees across multiple industry sectors, including banking and financial services, consumer goods, education, electronics, engineering, energy, government, healthcare, insurance, retail, technology, and telecommunications. The surveys were conducted 8-20 October 2021.

About IEEE

IEEE is the worlds largest technical professional organization dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics.Learn more

See the rest here:

Artificial Intelligence and Machine Learning, Cloud Computing, and 5G Will Be the Most Important Technologies in 2022, Says New IEEE Study - Dark...

November 20 2021

In the era of rapid advancement of artificial intelligence (AI) technology, robots equipped with artificial intelligence (AI) are becoming more intelligent and capable. , that is, the natural defense against the machines of professionals who win with creativity, inspiration, passion, and genius like ball games and stage shows is also weakened.

People often compare the human brain to a computer, neurons are like machines, and the brain is a program. The rise of artificial intelligence and the emergence of anthropomorphic robots makes seeing this metaphor even more fun.

However, Lisa Feldman-Barrett, a professor of psychology at Northeastern University in the US, believes this analogy is problematic and can lead to delusions.

image source,Getty Images

First, the memory of the human brain is a process and result of the continuous construction of electrical impulses and circulating chemicals, and the same memory can be reconsolidated in different ways at different times. The way computers store and process information is based on logic and machine learning procedures, which are not currently comparable to the human brain.

Second, the ability to recognize is one of the main components of artificial intelligence. For example, dandelion, artificial intelligence can accurately identify and identify this plant as a dandelion through learning; The human brain is different, and it will be classified according to its main function and role in different scenarios, such as associating vegetables with it, wildflowers, herbs and other designations.

Building this custom category may underlie the way the human brain works, Feldman-Barrett said.

Finally, the human brain is a part of the human body, where the central nervous system of the human body is located. This means the constant coordination and balance of dozens of indispensable organs, such as digestion, excretion, energy provision, disease control, as well as the regulation of emotions and the control of behavior.

image source,Science Pictures Company / Science Pictures Library

One of the main differences between human and machine is that humans have mental activities, but machines do not. The essence of mental activity is the control of the brain over the body.

Feldman Barrett writes: Every thought you have ever had, every concept you learned, every emotion you experienced, what you saw, heard, smelled, tasted, or everything you touch contains data on your physical state. You dont Experience your spiritual life That way, but thats what happens behind the scenes.

Your device does not support playing multimedia materials

Fan Hui: How do I see the relationship between humans and artificial intelligence

An anthropomorphic robot is equipped with artificial intelligence, but if you want it to think, feel, watch or act like a human, there has to be a complex system in place to adjust the body-like parts, maintain balance, and keep working. This must also be an ongoing interactive process.

Even if todays AI technology is close to this step, human emotions and emotionally-driven behaviors remain elusive by machines.

image source,Getty Images

From another perspective, Peter Bentley, a computer scientist at University College London, said that for at least a few hundred years, computers like the human brain will not emerge, until today humans can create vibrant colors and fragrances. The virtual world, and the increasingly sophisticated artificial intelligence.

He is the author of 10 Lessons in Artificial Intelligence, Robotics, and Digital Biology: How Nature is Changing Our Technology and Our Lives.

Bentley believes that even if computers can simulate the universe, the latest advances in artificial intelligence seem to show that a super-intelligent human brain can be simulated. The simulated world and the simulated brain are close to reality in evolution, but at least not in the world. foreseeable future. Be a reality.

He wrote on BBC Science Focus that the key is why do we do this? Why simulate the entire universe or the super-intelligent brain?

The superintelligence of the future is like a god for humanity, and humanity may not be able to understand or control what it chooses to do. Why create yourself a ubiquitous virtual god?

From a technical point of view, according to Moores Law, there are 2.6 trillion transistors on a computer chip, and the capacity of a computer doubles approximately every 20 months. At this speed, future computer processors will have powerful capabilities that are unimaginable today.

However, it took 13.8 billion years for the universe to form, and simulating this universe could take billions of years before it started working.

Bentley believes that within the next few hundred years, humans will likely use limited resources to invent artificial gravity or quantum teleportation, rather than simulating the entire universe or super-intelligent brains.

More:

The gap between the human brain and modern artificial intelligence - BBC News - Aviation Analysis Wing

MOSCOW, November 21. /TASS/. Artificial intelligence (AI) operators must have user control and be able to prevent wrong decisions with legal consequences made by the AI, Director of the Center for legal assistance to individuals in the digital environment Lyudmila Kurovskaya told TASS.

"The principle of user control must be applied while using artificial intelligence. The bottom line is that artificial intelligence operators have the liberty to disagree with the solution proposed by artificial intelligence and come up with their own. The ability of human operators to prevent erroneous judgments with legal repercussions produced by artificial intelligence is the principle of user control," she said.

According to Kurovskaya, only people should be held accountable for the repercussions of artificial intelligence judgments, including those responsible for the AI system's development, implementation, and use.

Today, Russian legislation has broad guidelines that apply to circumstances involving the use of artificial intelligence. Nonetheless, there is no specialized legislation on AI, not only in Russia but also globally, Chief legal expert at the General Radio Frequency Center Denis Sadovnikov told TASS.

According to the expert, because AI is now most commonly regarded as machine learning systems and other data-driven systems, it is critical to fully comply with data processing standards and subject rights. This is the current dominant worldwide perspective, not only in academics but also in practice.

Visit link:

AI should be used in line with user control principle - expert - TASS

On September 23 and 24 2021, The Institute for Operations Research and the Management Sciences (INFORMS), along with the Association for Computing Machinery Special Interest Group on Artificial Intelligence and the Computing Community Consortium, launched a new virtual workshop focusing on improving collaboration between the fields of artificial intelligence and operations research, as part of the INFORMS AI Initiative.

The workshop was organized by a team of seven researchers from universities across the United States, including Assistant Professor in the Daniel J. Epstein Department of Industrial and Systems Engineering, Phebe Vayanos, and USC Viterbi Professor of Computer Science, Sven Koenig.

The workshop included over 60 participants from academia, industry and government, all working within the fields of AI and operations research.

The event was the first of a three-part series focused on how AI and operations research can aid decision-making and maximize societal impact in the face of a world that is being transformed due to the COVID-19 pandemic and technological change, as well as the need to address widening inequalities and sustainable solutions for our food, water and energy needs into the future.

Participants in the September workshop reviewed the current state of research across both fields and discussed where research and education opportunities could be harnessed. The participants also identified the grand societal problems for which operations and AI research could present promising solutions covering societal challenges such as supply chains, sustainable energy, health care and crisis management, equitable transportation, and the modeling of human behavior on digital and physical platforms.

The next two workshops are expected to be held in the first half of 2022.

For more information about the event, read the full reporthere.

Published on November 17th, 2021

Last updated on November 17th, 2021

Read more:

Workshop Series Explores the Future of Artificial Intelligence and Operations Research - USC Viterbi | School of Engineering - USC Viterbi School of...

Sanofi invests $180 million equity in Owkins artificial intelligence and federated learning to advance oncology pipeline

PARIS November 18, 2021 Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, witha total payment of $90 million for three years plus additional research milestone-based payments. Owkin, an artificial intelligence (AI) and precision medicine company, builds best-in-class predictive biomedical AI models and robust data sets. With the ambition to optimize clinical trial design and detect predictive biomarkers for diseases and treatment outcomes, this collaboration will support Sanofis growing oncology portfolio in core areas such as lung cancer, breast cancer and multiple myeloma.

To accelerate medical research with AI in a privacy-preserving way, Owkin has assembled a global research network powered by federated learning, which allows data scientists to securely connect to decentralized, multi-party data sets and train AI models without having to pool data. This approach will complement Sanofis emerging strength in oncology, as the companys scientists apply cutting-edge technology platforms to design potentially life-transforming medicines for cancer patients worldwide.

"Owkins unique methodology, which applies AI on patient data from partnerships with multiple academic medical centers, supports our ambition to leverage data in innovative ways in R&D, said Arnaud Robert, Executive Vice President, Chief Digital Officer, Sanofi. We are striving to advance precision medicine to the next level and to discover innovative treatment methods with the greatest benefits for patients.

Sanofi will leverage the comprehensive Owkin Platform, in order to find new biomarkers and therapeutic targets, building prognostic models, and predicting response to treatment from multimodal patient data. Sanofis investment will support Owkins development and goal to grow the worlds leading histology and genomic cancer database from top oncology centers.

Owkins mission is to improve patients lives by using our platform to discover and develop the right treatment for every patient, said Thomas Clozel, M.D., Co-Founder and CEO at Owkin. We believe that the future of precision medicine lies in technologies that can unlock insights from the vast amount of patient data in hospitals and research centers in a privacy-preserving and secure way. This landmark partnership with Sanofi will see federated learning used to create research collaborations at a truly unprecedented scale. The future of AI to transform how we develop treatments is incredibly bright, and we are proud to partner with Sanofi on this mission.

This collaboration agreement will allow Sanofi to work closely with Owkin in identifying new oncology treatments across four cancers.

We look forward to working with our colleagues at Owkin to analyze data from hundreds of thousands of patients, said John Reed, M.D., Ph.D., Global Head of Research and Development, Sanofi. Sanofi's investment in the company includes a three-year agreement that will help discover and develop new treatments for non-small cell lung cancer, triple negative breast cancer, mesothelioma and multiple myeloma. This partnership will help accelerate our ambitious oncology program as we advance a rich pipeline of medicines to address unmet patient needs.

About Owkin

Owkin is a French American startup that specializes in AI and federated learning for medical research. It was co-founded in 2016 by Dr Thomas Clozel M.D., a clinical research doctor and former assistant professor in clinical hematology, and Dr Gilles Wainrib, Ph.D., a pioneer in the field of artificial intelligence in biology. Owkin has recently published groundbreaking research at the frontier of AI and medicine in Nature Medicine, Nature Communications and Hepatology. The Owkin Platform connects life science companies with world-class academic researchers and hospitals to share deep medical insights for drug discovery and development. Using federated learning and breakthrough collaborative AI technology, Owkin enables its partners to unlock siloed datasets while protecting patient privacy and securing proprietary data. Through sharing high-value insights, the company powers unprecedented collaboration to improve patient outcomes. Owkin works with the most prominent cancer centers and pharmaceutical companies in Europe and the US. Key achievements to date include HealthChain and MELLODDY; two Owkin led federated learning consortia fuelling unprecedented collaboration in academic research and drug discovery, respectively. For more information, please visit Owkin.com and follow @OWKINscience on Twitter.

About SanofiSanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Media Relations ContactsSally BainTel: +1 (781) 264-1091Sally.Bain@sanofi.com

Nicolas Obrist Tel: + 33 6 77 21 27 55Nicolas.Obrist@sanofi.com

Investor Relations Contacts ParisEva Schaefer-JansenArnaud DelepineNathalie Pham

Investor Relations Contacts North AmericaFelix Lauscher

Tel.: +33 (0)1 53 77 45 45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact

Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. Although Sanofis management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofis ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Sanofis annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

See the original post here:

Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline - GlobeNewswire